#USA #Las Vegas #CLTI #REVA Medical #MOTIV

Introduction

At the recent Vascular InterVentional Advances (VIVA) 2026 conference in Las Vegas, REVA Medical, LLC unveiled promising advancements in treatments for chronic limb-threatening ischemia (CLTI). The conference marked a pivotal moment for the company as it showcased a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable scaffold, and revealed late-breaking clinical trial results that could reshape vascular treatment protocols.

Live Case Demonstration

During the VIVA26 event, Professor Andrej Schmidt from the University Hospital Leipzig performed a crucial live case, demonstrating below-the-knee revascularization on a 72-year-old female patient suffering from nonhealing ulcers due to advanced CLTI, categorized as Rutherford 5. The procedure utilized two MOTIV scaffolds—a 4.0 mm × 48 mm and a 3.5 mm × 24 mm—leading to successful revascularization of the targeted peripheral artery and excellent angiographic outcomes. This groundbreaking execution not only emphasized the effectiveness of the MOTIV technology but also offered attendees a real-time insight into its clinical application.

Late-Breaking Clinical Trial Insights

Further enriching the conference was a groundbreaking presentation by Dr. Ehrin Armstrong from the HCA HealthOne Swedish Medical Center, who shared important results from the MOTIV pivotal trial. This randomized controlled trial involved 292 patients suffering from either Rutherford Category 4 or 5 CLTI, comparing the efficacy of MOTIV to standard balloon angioplasty.

The findings were striking. At the six-month mark, 87.2% of Rutherford 4 patients treated with the MOTIV scaffold achieved successful outcomes, compared to 76.3% who underwent PTA. For those classified under Rutherford 5, the MOTIV scaffold yielded results in 77.0% of cases, while PTA only managed a rate of 55.8%. After a year, the gap remained significant, with 76.7% and 65.7% of MOTIV-treated patients achieving success in Rutherford 4 and 5, respectively, compared to 54.5% and 46.2% for PTA.

Significance of Findings

What stands out in this analysis is MOTIV’s superiority in complex cases. The trial’s older patient population and their complicated CLTI scenarios underscore the importance of innovative solutions like that provided by REVA Medical. As Jeffrey Anderson, President and CEO of REVA Medical, stated, “Today’s live case demonstration and the late-breaking MOTIV results brought the potential of our bioresorbable scaffold technology into sharp focus.” These developments reflect the increasing need for improved methodologies in addressing severe vascular conditions.

Conclusion

The recent VIVA26 conference not only showcased REVA Medical's cutting-edge technology but also highlighted an ongoing commitment to advancing patient care within the vascular sector. As the field continues evolving, advancements like the MOTIV scaffold reflect a commitment to improving outcomes for patients battling CLTI. This initiative positions REVA Medical favorably within a competitive and innovative landscape, ensuring that complex vascular issues will receive the attention and solutions they critically need.